← All drugs Report issue

cp-601927

Small moleculeexperimental

Clinical trial activity

2 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

1

Phase 3

0

Phase 4

0

Earliest trial started Jun 1, 2010 (NCT01098240)

Timeline

2010s

Jan 1, 2010
Earliest Phase 2 Sponsor(trial)
Jan 1, 2011
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Neuronal acetylcholine receptor; alpha4/beta2PARTIAL AGONIST
Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
- Neuronal acetylcholine receptor subunit beta-2 (CHRNB2) ↗
- Neuronal acetylcholine receptor subunit alpha-4 (CHRNA4) ↗
- Neuronal acetylcholine receptor protein beta-2 subunit
- Neuronal acetylcholine receptor protein alpha-4 subunit

Chemistry & pharmacology

Loading structure…

SMILES

FC(F)(F)c1ccc2c(c1)[C@H]1CNC[C@@H]2C1

Mol. weight: 227.23 g/mol
Lipinski Ro5: Pass
Rule of 3: Yes
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL3707250 ↗
ChEMBLCHEMBL3341965 ↗

Also known as

cp-601927
cp-601927
cp-601927
cp-601,927
cp-601,927

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01396135	Phase 1	Aug 1, 2011	Pfizer
NCT01098240	Phase 2	Jun 1, 2010	Pfizer

Showing 2 of 2 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Pfizer	For profit	2	2	2	2010

1 organizations

Page 1 / 1